MXPA06013585A - Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them. - Google Patents

Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them.

Info

Publication number
MXPA06013585A
MXPA06013585A MXPA06013585A MXPA06013585A MXPA06013585A MX PA06013585 A MXPA06013585 A MX PA06013585A MX PA06013585 A MXPA06013585 A MX PA06013585A MX PA06013585 A MXPA06013585 A MX PA06013585A MX PA06013585 A MXPA06013585 A MX PA06013585A
Authority
MX
Mexico
Prior art keywords
methods
pharmaceutical formulations
making
acid secretion
formulations useful
Prior art date
Application number
MXPA06013585A
Other languages
Spanish (es)
Inventor
Warren Hall
Kay Olmstead
Gerald T Proehl
Original Assignee
Santarus Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santarus Inc filed Critical Santarus Inc
Publication of MXPA06013585A publication Critical patent/MXPA06013585A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The present invention relates to pharmaceutical formulations comprising at least one acid-labile proton pump inhibiting agent and at least one antacid, which have improved bioavailability, chemical stability, physical stability, dissolution profiles, disintegration times, safety, as well as other improved pharmacokinetic, pharmacodynamic, chemical and/or physical properties. The present invention is directed to methods, kits, combinations, and compositions for treating, preventing or reducing the risk of developing a gastrointestinal disorder or disease, or the symptoms associated with, or related to, a gastrointestinal disorder or disease in a subject in need thereof.
MXPA06013585A 2004-05-25 2005-05-25 Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them. MXPA06013585A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57464604P 2004-05-25 2004-05-25
US57466304P 2004-05-25 2004-05-25
PCT/US2005/018585 WO2005115474A1 (en) 2004-05-25 2005-05-25 Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them

Publications (1)

Publication Number Publication Date
MXPA06013585A true MXPA06013585A (en) 2009-07-22

Family

ID=35450661

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA06013585A MXPA06013585A (en) 2004-05-25 2005-05-25 Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them.

Country Status (5)

Country Link
EP (1) EP1750767A4 (en)
JP (1) JP2008500365A (en)
CA (1) CA2566655C (en)
MX (1) MXPA06013585A (en)
WO (1) WO2005115474A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2459393B (en) * 2006-10-05 2010-09-08 Santarus Inc Novel capsule formulation for the proton pump inhibitor omeprazole
EP2647381A4 (en) * 2010-12-03 2015-12-23 Takeda Pharmaceutical Orally disintegrating tablet
JP6641626B2 (en) * 2015-12-25 2020-02-05 エスエス製薬株式会社 Antacid pharmaceutical composition
KR102080023B1 (en) * 2018-01-29 2020-02-21 주식회사 종근당 Stable pharmaceutical composition comprising esomeprazole and sodium bicarbonate
KR102006777B1 (en) * 2018-01-29 2019-10-08 주식회사 종근당 Pharmaceutical formulation comprising esomeprazole and sodium bicarbonate
WO2020040438A1 (en) * 2018-08-23 2020-02-27 주식회사 종근당 Pharmaceutical preparation having excellent dissolution properties, containing esomeprazole and sodium bicarbonate
MX2022000968A (en) * 2019-07-26 2022-02-14 Chong Kun Dang Pharmaceutical Corp Stable pharmaceutical composition comprising esomeprazole and sodium bicarbonate.
KR102573842B1 (en) * 2020-02-21 2023-09-01 주식회사 종근당 Pharmaceutical composition comprising esomeprazole and sodium bicarbonate having improved drug release properties

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
US5622719A (en) 1993-09-10 1997-04-22 Fuisz Technologies Ltd. Process and apparatus for making rapidly dissolving dosage units and product therefrom
US6489346B1 (en) * 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6699885B2 (en) 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US6645988B2 (en) * 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
DE60237087D1 (en) * 2001-06-01 2010-09-02 Pozen Inc PHARMACEUTICAL COMPOSITIONS FOR THE COORDINATED DELIVERY OF NSAID
AR045062A1 (en) * 2003-07-18 2005-10-12 Santarus Inc PHARMACEUTICAL FORMULATIONS TO INHIBIT THE SECRETION OF ACID AND METHODS TO PREPARE AND USE THEM
WO2005076987A2 (en) * 2004-02-10 2005-08-25 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and nonsteroidal anti-inflammatory agent
CA2561700A1 (en) * 2004-04-16 2005-12-15 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and prokinetic agent

Also Published As

Publication number Publication date
WO2005115474A1 (en) 2005-12-08
CA2566655A1 (en) 2005-12-08
JP2008500365A (en) 2008-01-10
EP1750767A4 (en) 2010-09-22
WO2005115474B1 (en) 2006-02-23
CA2566655C (en) 2013-04-16
EP1750767A1 (en) 2007-02-14

Similar Documents

Publication Publication Date Title
WO2006127044A3 (en) Pharmaceutical formulations useful for inhibiting acid secretion
MXPA06013585A (en) Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them.
WO2008067037A3 (en) Novel formulations of proton pump inhibitors and methods of using these formulations
TW200509923A (en) A novel formulation, omeprazole antacid complex-immediate release, for rapid and sustained suppression of gastric acid
WO2010030781A3 (en) Aromatic carboxylic acid derivatives for treatment and prophylaxis of gastrointestinal diseases including colon cancer
TN2009000111A1 (en) Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
TNSN07341A1 (en) Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer
BRPI0518205A (en) use of (z) -2-cyano-3-hydroxy-but-2-enoic acid (4'-trifluoromethylphenyl) -amide for the treatment of inflammatory bowel disease
BRPI0910182A2 (en) compound of formula (i), pharmaceutical composition, method of treating a disorder and use of a compound "
TW200510349A (en) Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor
MX2009006056A (en) Ph sensitive matrix formulation.
WO2006031922A3 (en) Thyroid hormone analogs for promoting angiogenesis
NO20064347L (en) Substituted 1,2,3,4-tetrahydroisoquinoline derivatives
MX2009004362A (en) Benzoyl amino heterocyclyl compounds useful in the treatment of a disease mediated through glk.
IS6557A (en) Mixed medical treatment of antihypertensive agents and anti-angiogenic agents
SG153667A1 (en) Method of treating atherosclerosis, dyslipidemias and related conditions and pharmaceutical compositions
ATE521343T1 (en) COMPOSITIONS OF RASAGILIN THAT DISSOLVE IN THE MOUTH
MX2010000801A (en) Improved pharmaceutical composition containing dihydropyridine calcium channel antagonist and method for the preparation thereof.
NO20084542L (en) Pharmaceutical combination containing 3- (3-dimethylamino-1-ethyl-2-methyl-propyl) -phenol and paracetamol
WO2011141685A3 (en) Systemic nasal compositions comprising cocoyl proline or at least one of the constituents thereof
DK1951659T3 (en) Glucagon Receptor Antagonists, Preparation and Therapeutic Use thereof
WO2009045291A3 (en) Mast cell stabilizers in the treatment of obesity
WO2007084541A3 (en) Central administration of stable formulations of therapeutic agents for cns conditions
TW200745081A (en) Compounds
UA86399C2 (en) Normal;heading 1;heading 2;USE OF 2,5-DIHYDROXYBENZENESULPHONIC ACID IN THE PRODUCTION OF MEDICAMENTS FOR THE TREATMENT OF ANGIODEPENDENT DISEASES

Legal Events

Date Code Title Description
FG Grant or registration